Association of loss of heterozygosity with shorter survival in primary glioblastoma patients

Polish Journal of Pathology

Volumn 64, Issue 4, 2013, Pages 268-275

  Jesionek Kupnicka, Dorota ^a   Szybka, Małgorzata ^a   Potemski, Piotr ^a   Kulczycka Wojdala, Dominika ^a   Jaskólski, Dariusz ^b   Bieńkowski, Michał ^a   Skowroński, Wiesław ^c   Papierz, Wielisław ^a   Kordek, Radzisław ^a   Zawlik, Izabela ^d  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Medical University of Lodz Copernicus Memorial Hospital ^*  (Poland)

^c Perzyna Memorial Specialistic Hospital   (Poland)

^d UNIVERSITY OF RZESZÓW   (Poland)

Author keywords

10q; 13q and 17p; 19q; 9p; Glioblastoma; LOH 1p; Survival

Indexed keywords

DNA; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL; ARTICLE; CHEMISTRY; CHROMOSOME 1; CHROMOSOME 19; CHROMOSOME DELETION; DNA SEQUENCE; FEMALE; GENE DELETION; GENETICS; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MISSENSE MUTATION; MORTALITY; PROGNOSIS; YOUNG ADULT;

ADULT; AGED; ANIMALS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84891472446     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/PJP.2013.39335     Document Type: Article

References (41)

1. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-6899.
2. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489.
3. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
4. Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol 2003; 10: 212-217.
5. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 2007; 131: 242-251.
6. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
7. Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation andMGMT promoter methylation in gliomas: use with caution. Mod Pathol 2013; 26: 922-929.
8. Jesien-Lewandowicz E, Jesionek-Kupnicka D, Zawlik I, et al. High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. Cancer Genet Cytogenet 2009; 188: 77-82.
9. Adamek D, Zazula M, Radwańska E, et al. Co-occurrence of MGMT gene promoter methylation and amplification of EGFR in glioblastoma. Contemp Oncol (Pozn) 2011; 15: 362-366.
10. Birner P, Toumangelova-Uzeir K, Natchev S, Guentchev M. Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. Folia Neuropathol 2011; 49: 88-93.
11. Labussière M, Idbaih A, Wang XW, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010; 74: 1886-1890.
12. Ueki K, Nishikawa R, Nakazato Y, et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002; 8: 196-201.
13. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63: 6962-6970.
14. Kaneshiro D, Kobayashi T, Chao ST, et al. Chromosome 1p and 19q deletions in glioblastoma multiforme. Appl Immunohistochem Mol Morphol 2009; 17: 512-516.
15. Nakamura M, Yang F, Fujisawa H, et al. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. JNeuropathol Exp Neurol 2000; 59: 539-554.
16. Ino Y, Zlatescu MC, Sasaki H, et al. Long survival and therapeutic responses in patients with histologically disparate highgrade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000; 92: 983-990.
17. Homma T, Fukushima T, Vaccarella S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 2006; 65: 846-854.
18. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype andmorphology on the prognosis of glioblastoma. JNeuropathol Exp Neurol 2002; 61: 321-328.
19. Houillier C, Lejeune J, Benouaich-Amiel A, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006; 106: 2218-2223.
20. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-5750.
21. Pinto LW, Araújo MB, Vettore AL, et al. Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch 2008; 452: 481-490.
22. Tada K, Shiraishi S, Kamiryo T, et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. JNeurosurg 2001; 95: 651-659.
23. Fujisawa H, Reis RM, Nakamura M, et al. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000; 80: 65-72.
24. Kleihus P, Burger PC, Aldape KD, et al. Glioblastoma. In: WHO classification of tumours of the central nervous system. Louis DN, Khaki H,Wiestler OD, CaveneeWK (eds.). IARC Press, Lyon, France 2007; 33-49.
25. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997; 3: 523-530.
26. Karsy M, Gelbman M, Shah P, et al. Established and emerging variants of glioblastoma multiforme: review ofmorphological and molecular features. Folia Neuropathol 2012; 50: 301-321.
27. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013; 19: 764-772.
28. Rieske P, Golanska E, Zakrzewska M, et al. Arrested neural and advancedmesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors. BMC Cancer 2009; 9: 54.
29. Salvati M, Formichella AI, D'Elia A, et al. Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. JNeurooncol 2009; 94: 129-134.
30. Mollenhauer J, Wiemann S, Scheurlen W, et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25. 3-26.1 is deleted in malignant brain tumours. Nat Genet 1997; 17: 32-39.
31. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
32. Knobbe CB, Merlo A, Reifenberger G. PTEN signaling in gliomas. Neuro Oncol 2002; 4: 196-211.
33. Motomura K, Mittelbronn M, Paulus W, et al. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome. J Neuropathol Exp Neurol 2012; 71: 702-707.
34. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
35. Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 2005; 576: 22-38.
36. Rasheed A, Herndon JE, Stenzel TT, et al. Molecular markers of prognosis in astrocytic tumors. Cancer 2002; 94: 2688-2697.
37. Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 2001; 81: 77-82.
38. Vordermark D, Ruprecht K, Rieckmann P, et al. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer 2006; 6: 247.
39. He J, Mokhtari K, SansonM, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 2001; 60: 863-871.
40. Miller CR, Perry A. Glioblastoma. Arch Pathol LabMed 2007; 131: 397-406.
41. Hegi ME, Janzer RC, Lambiv WL, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol 2012; 123: 841-852.